Publications, Pharmaceutical

Evaluation of Albuterol Sulfate with Low Global Warming Potential Propellants

Reformulating widely used inhaled medications with propellants with a lower global warming potential is an important strategy for improving the sustainability of respiratory therapies.

This paper presents experimental data for a reformulated propellant-only formulation of albuterol sulfate in HFA-152a, a relatively low global warming potential propellant. Aerodynamic particle size distribution data were generated and used to predict regional deposition of the albuterol sulfate. Drug absorption was predicted using a pharmacokinetic model. The results demonstrate the feasibility of producing a stable pressurized metered dose inhaler formulation of albuterol sulfate using HFA-152a. Central deposition behavior was observed to be comparable to a current commercial product (Ventolin).

Download Publication
15 May 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

14 Dec 2022

Building Digital Solutions To Meet The Unique Therapeutic Needs o...

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
25 Nov 2022

Analytical Services in the Development of MDIs and DPIs

Brochures, Pharmaceutical, Innovation & Insights, Product Solutions

Read More
16 Nov 2022

From pMDI Device to Therapeutic Effect

Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions, Sustainability

Read More
21 Oct 2022

Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations

Read More
1 2 3 15
Back To Top